Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways associated with response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab govitecan and 177Lu-PSMA-617, respectively. This breakthrough in identifying resistance mechanisms provides crucial insights for personalized treatment strategies, potentially improving patient outcomes and reducing unnecessary side effects. By pinpointing specific molecular pathways linked to resistance, clinicians can tailor treatment plans to target these mechanisms, enhancing the effectiveness of cancer therapies.
Read more from news.search.yahoo.com
